PUBBLICAZIONI

Ecco le nostre pubblicazioni

EMOFILIA A

Extended half-life RFVIII for the treatment of Hemophilia A: drugs consumption and patients’ perspective.

Daniela Paola Roggeri, Ezio Zanon, Chiara Biasoli, Alessandro Roggeri. Health Economics And Therapeutic Pathways 2020; 21(1): 59-67.

NEFROLOGIA

Cinacalcet adherence in dialysis patients with secondary hyperparathyroidism in Lombardy Region: clinical implications and costs.

Roggeri A, Conte F, Rossi C, Cozzolino M, Zocchetti C, Roggeri DP. Drugs In Context 2020; 9: 2020-1-1.

NEFROLOGIA-TRAPIANTI

Real-world data on healthcare resource consumption and costs before and after kidney transplantation.

Roggeri DP, Roggeri A, Zocchetti C, Cozzolino M, Rossi C, Conte F. Clin Transplant. 2019 Oct;33(10):e13728.

DIABETE

Optimization of treatment with exenatide once weekly versus basal insulins for patients with type 2 diabetes: a budget impact analysis.

Roggeri A, Nicolucci A and Roggeri DP. SM J Clin Med. 2018; 4(2): 1036s.

MALATTIE RESPIRATORIE

L’impatto clinico e organizzativo delle malattie respiratorie croniche: quale futuro per la pneumologia?

C. Micheletto, A. Roggeri, D.P. Roggeri e F. De Michele. Rassegna di Patologia dell’Apparato Respiratorio. 2017; 32: 202-209.

GASTROENTEROLOGIA

Economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in italy.

Roggeri DP and Roggeri A. Hepatic Medicine: Evidence and Research 2017:9 37–43. doi: 10.2147/HMER.S146438. eCollection 2017.

EMOFILIA A

Recently approved recombinant factor VIII (rfVIII) for the replacement treatment in patients with hemophilia A in Italy.

Roggeri DP, Zanon E, Roggeri A. Farmeconomia. Health Economics and Therapeutic Pathways 2017; 18(1): 55-60

MALATTIE RESPIRATORIE

Impact of hospitalizations for bronchiolitis in preterm infants on long-term health care costs in Italy: a retrospective case-control study.

Roggeri DP, Roggeri A, Rossi E, Cataudella S, Martini N. Clinicoecon Outcomes Res. 2016 Aug 4;8:407-12. doi: HTTP://DX.DOI.ORG/10.2147/CEOR.S111535. eCollection 2016.

EMOFILIA A

Kovaltry® for the replacement therapy in patients with Hemophilia

A. Roggeri DP, Colombo A, Roggeri A. Farmaeconomia, health economis and therapeutic pathways. Vol 17, No 2 (2016).

NEFROLOGIA

Healthcare costs of the progression of chronic kidney disease and different dialysis techniques estimated through administrative database analysis.

Roggeri A, Roggeri DP, Zocchetti C, Bersani M, Conte F; ReNe (Renal Lombardy Network); Additional contributors from ReNe Network. J Nephrol. 2017 Apr;30(2):263-269.. doi: 10.1007/s40620-016-0291-8. Epub 2016 May 10.

MALATTIE RESPIRATORIE

Inhalation errors due to device switch in patients with chronic obstructive pulmonary disease and asthma: critical health and economic issues.

Roggeri A , Micheletto C , Roggeri DP. Int J Chron Obstruct Pulmon Dis. 2016 Mar 21;11:597-602. doi: 10.2147/COPD.S103335. eCollection 2016.

NEFROLOGIA

End-stage Renal Disease Costs for Patients New to Hemodialysis in Italy: The FARO-2 Study.

Roggeri DP, Roggeri A, Brancaccio D, Mazzaferro S, Messa P, Paoletti E, Possidoni A, Costanzo AM, di Luzio Paparatti U, Cozzolino M and On behalf of the FARO-2 Study Group. British Journal of Medicine and Medical Research, ISSN: 2231-0614,Vol. 12, Issue. 5

NEFROLOGIA

Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the FARO-2 study.

Roggeri DP, Cozzolino M, Mazzaferro S, Brancaccio D, Paoletti E, Roggeri A, Costanzo AM, di Luzio Paparatti U, Festa V, Messa P. Int J Nephrol Renovasc Dis. 2014 Dec 16;8:1-6. doi: 10.2147/IJNRD.S72011. eCollection 2015.

GASTROENTEROLOGIA

Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs.

Roggeri DP, Roggeri A, Rossi E, Cinconze E, Gasbarrini A, Monici Preti P, De Rosa M. Hepat Med. 2015 Jul 13;7:37-42. doi: 2147/HMER.S87594. eCollection 2015.

NEFROLOGIA

Health economic evaluation of paricalcitol® versus cinacalcet + calcitriol (oral) in Italy.

Nuijten M, Roggeri DP, Roggeri A, Novelli P, Marshall TS. Clin Drug Investig. 2015 Apr;35(4):229-38. doi: 10.1007/s40261-014-0264-4

MALATTIE CARDIOVASCOLARI

Venous tromboembolism treatment: budget impact analysis of rivaroxaban in Italy.

Roggeri DP, Roggeri A, Pengo V, Farmaeconomia, health economis and therapeutic pathways 2014, 15(4) 113-127. HTTP://DX.DOI.ORG/10.7175/FE.V15I4.968

NEFROLOGIA

Chronic Kidney Disease: Evolution Of healthcare Costs And Resource Consumption From Predialysis To Dialysis In Piedmont Region, Italy.

Daniela Paola Roggeri, Alessandro Roggeri and Mario Salomone. Advances In Nephrology, Vol. 2014, article ID 680737, 6 pages, 2014. DOI:10.1155/2014/680737

CARDIOLOGIA

Gender, socioeconomic position, revascularization procedures and mortality in patients presenting with stemi and nstemi in the era of primary PCI. Differences or inequities?

Roberto Gnavi, Raffaella Rusciani, Marco Dalmasso, Massimo Giammaria, Monica Anselmino, Daniela Paola Roggeri and Alessandro Roggeri. International Journal of Cardiology 176 (2014) 724–730, http://dx.doi.org/10.1016/j.ijcard.2014.07.107

MALATTIE RESPIRATORIE

Outcomes and costs of treating chronic obstructive pulmonary disease with inhaled fixed combinations: the italian perspective of the pathos study.

Alessandro Roggeri, Claudio Micheletto and Daniela Paola Roggeri. International Journal of Chronic Obstructive Pulmonary Disease. 2014:9 569–576

CARDIOLOGIA

Resource consumption and healthcare costs of acute coronary syndrome: a retrospective observational administrative database analysis.

Alessandro Roggeri, Roberto Gnavi, Marco Dalmasso, Raffaella Rusciani, Massimo Giammaria, Monica Anselmino and Daniela Paola Roggeri. Crit Pathw Cardiol. 2013 dec;12(4):204-9. doi: 10.1097/hpc.0b013e3182a78c06.

CARDIOLOGIA

Outcomes, health costs and use of antiplatelet agents in 7082 patients admitted for an Acute Coronary Syndrome occurring in a large community setting.

AP Maggioni, E Rossi, E Cinconze, DP Roggeri, A Roggeri, A Fabbri and M De Rosa, on the behalf of the ARNO Cardiovascular Observatory. Cardiovascular Drugs and Therapy , March 2013 DOI:10.1007/s10557-013-6455-z

SCLEROSI MULTIPLA

Uso di database amministrativi per la rilevazione di consumo di risorse e spesa per pazienti affetti da sclerosi multipla nella Regione Piemonte.

Roggeri, D.P., Roggeri, A. & Jommi, C. Pharmacoeconomics-Ital-Res-Articles 14, 79–89 (2012). https://doi.org/10.1007/BF03337456

NEFROLOGIA

La malattia renale e le sue complicanze: percorso per una diagnosi precoce e gestione multidisciplinare.

G Annoni, D. Brancaccio, R. Coppo, M.G. Cozzolino, C. Cricelli, F. Fedele, DP. Roggeri, R Trevisan. Italian health Policy Brief. Ottobre 2012.

CARDIOLOGIA

Outcomes intraospedalieri, consumo di risorse sanitarie e costi per il trattamento di pazienti con sindrome coronarica acuta.

DP. Roggeri, A. Roggeri, E. Rossi. E. Cinconze. Cardiolink maggio 2012.

MALATTIE RESPIRATORIE

Palivizumab nella profilassi del virus respiratorio sinciziale: analisi di impatto sul budget del SSN italiano.

DP. Roggeri Farmeconomia e Percorsi Terapeutici; 2011;12 (suppl.3): 17-23

DOLORE

Analisi dell’utilizzo di Oppioidi forti in Italia.

DP. Roggeri. NEW BIFE il consumo dei farmaci analgesici in Italia.

INFETTIVOLOGIA

HIV/AIDS: evoluzione nel mix di consumo di risorse e costi di trattamento.

DP Roggeri. Focus On Farmacoeconomia 2009. .

DOLORE

Consumi e costi dei farmaci a carico del Servizio Sanitario Nazionale per il trattamento del dolore oncologico.

D. Roggeri, P Giusti, A Chinellato. Quaderni di Farmacoeconomia 05 2008.

ONCOLOGIA

Resource consumption and costs of treating pain in patients affected by cancer in a district of northeast italy.

D Roggeri, C Saramin, G Terrazzani, Zusso M, P Giusti and A Chinellato. Pharmacological Reasearch 56: 329-334, 2007. DOI: 10.1016/j.phrs.2007.08.001

MALATTIE CARDIOVASCOLARI

Comparison of Fluvastatin + Fenofibrate combination therapy and Fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a twelve month, randomized, double-blind, controlled trial.

G. Derosa, A.F.G. Cicero, G. Bertone, M. Piccinini, L. Ciccarelli, D.P. Roggeri, R. Fogari. Clinical Therapeutics 26:8, 2004. DOI: 10.1016/j.clinthera.2004.10.008

DOLORE

I costi della terapia farmacologia del dolore: farmaci oppioidi e nuovi indicatori di consumo.

D Roggeri; Il Sole 24 Ore Sanità 29/06/2004.

DOLORE

I costi del dolore cronico/ricorrente in medicina generale.

L. Garattini, V. Caimi,S. Cipriani, D. Roggeri, D. Lanzeni, C. Viscarra e Gruppo di Studio PaCo. Pharmacoeconomics Italian Research Articles 5(3): 21-28, 2003

REUMATOLOGIA

Analisi di costo della terapia con celecoxib vs FANS tradizionali nell’artrosi, in Italia.

C. Lucioni, S. Chiroli, D. Roggeri, G. Annoni. Pharmacoeconomics Italian Research Articles 5(1): 23-34, 2003

DOLORE – GASTROENTEROLOGIA

Consumo di risorse e costi per la diagnosi e la cura degli eventi avversi gastrointestinali dovuti all’uso dei Farmaci Anti-infiammatori Non Steroidei (FANS): studio retrospettivo condotto presso i medici di medicina generale.

S. Chiroli, D. Roggeri. Pharmacoeconomics Italian Research Articles 3(2): 61-70,2001.

Torna alla home

2021

powered by DENANI SRL